Bär & Karrer advises Novartis on the acquisition of the Medicines Company
In connection with the acquisition of NASDAQ-listed biopharmaceutical company The Medicines Company for USD 9.7 billion, Novartis AG and Novartis Finance Corporation entered into a USD 7 billion short-term (bridge) credit agreement and completed a USD 5 billion four-tranche SEC-registered bond offering.
Bär & Karrer acted as Swiss legal advisor to Novartis in this transaction. The team included Thomas U. Reutter (pictured), Roland Truffer, Alexander von Jeinsen and Annette Weber (all capital markets and financing) as well as Susanne Schreiber and Kerim Tbaishat (both tax).
